EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Scaffold hopping yields novel furo[3,2-d]pyrimidine NNRTIs with optimized antiviral potency, enhanced selectivity, and reduced hERG liability

Yin-Xiang Zhang, Christophe Pannecouque, Erik De Clercq, Enzo Tramontano, Angela Corona, Laura Dettori, Phuong-Thao Tran, Xu-Dong Li, Shuo Su, Shuai Wang, Fen-Er Chen

Acta Pharmaceutica Sinica B · 2026-07 · 16 (7) · 4459-4477

DOI: 10.1016/j.apsb.2026.01.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2026-07. Verfasst von Yin-Xiang Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Engineering Center of Catalysis and Synthesis for Chiral Molecules, Shanghai Engineering Research Center of Industrial Asymm…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: State Key Laboratory of Natural and Biomimetic Drugs, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Considering the exceptional anti-HIV-1 potency of rilpivirine (RPV) against diverse mutant strains and its remarkable human ether-a-go-go related gene (hERG) potassium channel inhibition (IC 50 = 0.50 μmol/L) as well as low selectivity (SI = 3989), a series of novel furo-[3,2- d ]pyrimidine derivatives were rationally designed through a scaffold hopping strategy. Encouragingly, compound 10 revealed a striking reduction in hERG channel inhibition (IC 50 > 30 μmol/L) and significant increase in selectivity (SI = 161580). Notably, 10 exhibited excellent antiviral activity against various HIV-1 strains (EC 50 = 1.9−46.3 nmol/L). In particular, 10 displayed prominent inhibitory potency against Y188L (EC 50 = 15.5 nmol/L) and F227L+V106A strain (EC 50 = 8.7 nmol/L), which was superior to those of RPV (EC 50 (Y188L) = 79.4 nmol/L, EC 50 (F227L+V106A) = 81.6 nmol/L). Besides, no apparent cytotoxicity (CC 50 = 314.8 μmol/L) and negligible suppression of CYP isoenzymes were detected. Overall, these findings illustrated that 10 was a potentially promising NNRTI for HIV-1 therapy.

Schlagwörter

Stichwörter der Autor:innen

Diarylpyrimidine (DAPY)HIV-1Human ether-a-go-go related gene (hERG)Non-nucleoside RT inhibitors (NNRTIs)Reverse transcriptase (RT)

Autor:innen und Institutionen

  • Department of Chemistry, Engineering Center of Catalysis and Synthesis for Chiral Molecules, Shanghai Engineering Research Center of Industrial Asymmetric Catalysis of Chiral Drugs, State Key Laboratory of Green Chemica…
  • Rega Institute for Medical Research, KU Leuven, Leuven B-3000, Belgium.
  • Department of Life and Environmetal Sciences, University of Cagliari, Monserrato I-09042, Italy.
  • Department of Pharmaceutical Chemistry, Hanoi University of Pharmacy, Hoan Kiem, Hanoi 10000, Viet Nam.
  • School of Data Science, Shanghai, Fudan University, Shanghai 200433, China.
  • Shanghai Institute of Infectious Disease and Biosecurity, School of Public Health, Fudan University, Shanghai 200433, China.

Förderung

  • State Key Laboratory of Natural and Biomimetic Drugs
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, Y. X., Pannecouque, C., De Clercq, E., Tramontano, E., Corona, A., Dettori, L., Tran, P. T., Li, X. D., Su, S., Wang, S., & Chen, F. E. (2026). Scaffold hopping yields novel furo[3,2-d]pyrimidine NNRTIs with optimized antiviral potency, enhanced selectivity, and reduced hERG liability. Acta Pharmaceutica Sinica B, 16(7), 4459-4477. https://doi.org/10.1016/j.apsb.2026.01.010

Vancouver

Zhang YX, Pannecouque C, De Clercq E, Tramontano E, Corona A, Dettori L, et al. Scaffold hopping yields novel furo[3,2-d]pyrimidine NNRTIs with optimized antiviral potency, enhanced selectivity, and reduced hERG liability. Acta Pharmaceutica Sinica B. 2026;16(7):4459-4477. doi:10.1016/j.apsb.2026.01.010

BibTeX
@article{Zhang2026,
  author = {Zhang, Yin-Xiang and Pannecouque, Christophe and De Clercq, Erik and Tramontano, Enzo and Corona, Angela and Dettori, Laura and Tran, Phuong-Thao and Li, Xu-Dong and Su, Shuo and Wang, Shuai and Chen, Fen-Er},
  title = {Scaffold hopping yields novel furo[3,2-d]pyrimidine NNRTIs with optimized antiviral potency, enhanced selectivity, and reduced hERG liability},
  journal = {Acta Pharmaceutica Sinica B},
  year = {2026},
  volume = {16},
  number = {7},
  pages = {4459--4477},
  doi = {10.1016/j.apsb.2026.01.010}
}
Kostenlos starten →